Agios Pharmaceuticals AGIO Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's accrued expenses?
- Agios Pharmaceuticals (AGIO) reported accrued expenses of $11.69M in Q1 2026.
- How has Agios Pharmaceuticals's accrued expenses changed year-over-year?
- Agios Pharmaceuticals's accrued expenses increased by 49.8% year-over-year, from $7.8M to $11.69M.
- What is the long-term trend for Agios Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's accrued expenses has grown at a -2.4% compound annual growth rate (CAGR), from $30.8M to $27.26M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.